2014—2016年南京地区34家医院抗痛风药物的使用情况分析  

Analysis on utilization of anti-gout drugs in 34 hospitals from Nanjing area from 2014 to 2016

作　　者：李茜 顾中盛 LI Qian;GU Zhong-sheng(The First Affiliated Hospital with Nanjing Medical University,Nanjing 210029,China)

机构地区：[1]南京医科大学第一附属医院药学部,江苏南京210029

出　　处：《现代药物与临床》2018年第12期3361-3365,共5页Drugs & Clinic

摘　　要：目的对南京地区34家医院抗痛风药物的应用情况进行回顾性分析,为抗痛风药物的开发、生产、营销及合理利用提供参考和依据。方法对2014—2016年南京地区34家医院抗痛风药物的用量、销售金额、用药频度(DDDs)、日均药费(DDC)及药品排序比(B/A)等进行统计和分析。结果南京地区抗痛风药物的销售金额和DDDs都逐年增长,苯溴马隆连续两年占主导地位,增长率最快的药物均是减少尿酸合成的药物非布司他,4种药物的排序无明显变化。DDC最大的为非布司他,秋水仙碱的DDC最小。B/A比值接近1.00的品种别嘌醇和苯溴马隆。结论南京地区34家医院临床用药时基本能遵循指南要求选择合适的抗痛风药物,但供选择的药物品种少,有待开发新的药物。Objective To evaluate the clinical application of anti-gout drugs in 34 hospitals from Nanjing area, to provide the basis methods for the production, marketing, and clinical application of anti-gout drugs. Methods The utilization information of anti-gout drugs in 34 hospitals from Nanjing area from 2014 to 2016 was extracted, and the consumption sum, defined daily doses(DDDs), defined daily cost(DDC), and drug sequence ratio(B/A) were analyzed statistically. Results Consumption sum and DDDs of anti-gout drugs were both increased per year from 2014 to 2016. And benzbromarone occupied most marketing by two years. Among all the anti-gout drugs, febuxostat was the drugs with most obviously increased rate. The sequence of anti-gout drugs was stable. DDC of febuxostat was the highest, while DDC of colchicines was the lowest. Conclusion The application of anti-gout drugs in 34 hospitals from Nanjing area can follow the medication guide. But the varieties of anti-gout drugs is not abundant, it needs to develop the new drugs.

关 键 词：抗痛风药 销售金额 用药频度:南京地区 

分 类 号：R976[医药卫生—药品]